ImmunoLogic
Seattle, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $380M
Overview
Develops next-generation vaccines and immunotherapies for difficult-to-treat infectious diseases.
Infectious DiseaseImmunology
Technology Platform
A computational antigen design platform that engineers stabilized proteins to elicit broad immune responses, paired with a proprietary adjuvant system.
Funding History
1Total raised:$380M
PIPE$380M
Opportunities
Strong global demand for improved pandemic preparedness creates a favorable environment for funding and partnerships.
Risk Factors
Clinical failure to demonstrate meaningful superiority over existing vaccines is a key developmental risk.
Competitive Landscape
Competes with large vaccine makers (GSK, Sanofi) and biotechs like Moderna in the pursuit of universal vaccines.